Adrian Hugenmatter
Head of Protein Therapeutics, Stanford ChEM-H
Dr. Adrian Hugenmatter joined ChEM-H in 2021 and is leading the Protein Therapeutics Knowledge Center. Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich), where he gained his first experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he worked on molecular evolution. Dr. Hugenmatter then spent 11 years as a research scientist and team leader at Roche. During that time he developed and optimized several antibody lead candidates for therapeutic application in Oncology and Neuroscience. Dr. Hugenmatter has a high interest in protein evolution and engineering.